D. Moldvai

In Situ Analysis of mTORC1/C2 and Metabolism-Related Proteins in Pediatric Osteosarcoma

A. Sebestyén, M. Csóka, G. Arató, 2022, Pathology & Oncology Research.

mTOR hyperactivity and RICTOR amplification as targets for personalized treatments in malignancies

T. Dankó, G. Petővári, Viktória Varga, 2024, Pathology oncology research : POR.

Tumorigenic role of tacrolimus through mTORC1/C2 activation in post-transplant renal cell carcinomas

G. Végső, Á. Márk, T. Dankó, 2024, British journal of cancer.

The role of metabolic ecosystem in cancer progression — metabolic plasticity and mTOR hyperactivity in tumor tissues

A. Sebestyén, A. Jeney, T. Dankó, 2021, Cancer and Metastasis Reviews.

Characterisation of 3D Bioprinted Human Breast Cancer Model for In Vitro Drug and Metabolic Targeting

J. Pápay, A. Sebestyén, T. Dankó, 2022, International journal of molecular sciences.

3D bioprinting and the revolution in experimental cancer model systems—A review of developing new models and experiences with in vitro 3D bioprinted breast cancer tissue-mimetic structures

A. Sebestyén, T. Dankó, G. Petővári, 2023, Pathology & Oncology Research.

Cyclodextrin encapsulation enabling the anticancer repositioning of disulfiram: Preparation, analytical and in vitro biological characterization of the inclusion complexes.

I. Sebe, Z. Szabó, G. Tóth, 2024, International journal of pharmaceutics.

Metabolic Adaptation as Potential Target in Papillary Renal Cell Carcinomas Based on Their In Situ Metabolic Characteristics

E. Sebestyén, K. Mészáros, J. Pápay, 2022, International journal of molecular sciences.